Advanced Nanotechnology-Based Nucleic Acid Medicines
Nucleic acid medicines are a highly attractive modality that act in a sequence-specific manner on target molecules. To date, 21 such products have been approved by the Food and Drug Administration. However, the development of nucleic acid medicines continues to face various challenges, including tis...
Saved in:
| Main Authors: | Noriko Miyamoto, Mina Sakuragi, Yukio Kitade |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2024-10-01
|
| Series: | Pharmaceutics |
| Subjects: | |
| Online Access: | https://www.mdpi.com/1999-4923/16/11/1367 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Aptamer–ODN Chimeras: Enabling Cell-Specific ODN Targeting Therapy
by: Bei Xia, et al.
Published: (2025-05-01) -
Harnessing RNA therapeutics: novel approaches and emerging strategies for cardiovascular disease management
by: Wang Dui, et al.
Published: (2025-03-01) -
mRNA turnover rate limits siRNA and microRNA efficacy
by: Erik Larsson, et al.
Published: (2010-11-01) -
RNA interference and turnover in plants -a complex partnership
by: Michal Krzyszton, et al.
Published: (2025-07-01) -
Comprehensive analysis of lipid nanoparticle formulation and preparation for RNA delivery
by: Md. Anamul Haque, et al.
Published: (2024-12-01)